This is the authors' abstract. We don't add key points for this paper.
We present two patient cases (one with bladder carcinoma and one with renal cell carcinoma) who consulted our department of General Medical Oncology, after having been treated in other hospitals in two clinical trials with immune checkpoint inhibitors and having been dismissed from the trials after 5 months of therapy for progressive disease. They consulted to discuss consecutive treatment opportunities. However, longer follow-up has shown that both patients were dismissed equivocally from both trials. We are worried that equivocal response evaluation in the context of clinical trials with immune checkpoint inhibitors, due to pseudo-progression or delayed responses, can negatively impact trial outcomes as well as biomarker research.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kyriazoglou et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: